I
Ian Chopra
Researcher at University of Leeds
Publications - 159
Citations - 13589
Ian Chopra is an academic researcher from University of Leeds. The author has contributed to research in topics: Antibacterial agent & Escherichia coli. The author has an hindex of 56, co-authored 159 publications receiving 12349 citations. Previous affiliations of Ian Chopra include University of Ljubljana & British Society for Antimicrobial Chemotherapy.
Papers
More filters
Journal ArticleDOI
Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance
Ian Chopra,Marilyn C. Roberts +1 more
TL;DR: Changing the use of tetracyclines in human and animal health as well as in food production is needed if this class of broad-spectrum antimicrobials through the present century is to continue to be used.
Journal ArticleDOI
The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?
TL;DR: The clinical incidence of silver resistance remains low, and emergence of resistance can be minimized if the level of silver ions released from products is high and the bactericidal activity rapid.
Journal ArticleDOI
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections
TL;DR: Despite some drawbacks, membrane-active agents form an important new means of eradicating recalcitrant, non-growing bacteria.
Book ChapterDOI
Organic acids: chemistry, antibacterial activity and practical applications.
TL;DR: The chapter discusses two aspects of the use of organic acids: in animal husbandry as animal feed additives and in abattoirs and food-processing plants where they may be used in controlling microbial contamination of carcass meat.
Journal ArticleDOI
Discovery research: the scientific challenge of finding new antibiotics
David M. Livermore,Martin J. Blaser,Otto Carrs,Gail H. Cassell,Neil O. Fishman,Robert Guidos,Stuart B. Levy,John H. Powers,Ragnar Norrby,Glenn S. Tillotson,Rick Davies,Steven J. Projan,Michael J. Dawson,Dominique L Monnet,Marcus Keogh-Brown,Kieran Hand,Sarah Garner,David Findlay,Chantal M. Morel,Richard Wise,Richard Bax,Frances Burke,Ian Chopra,Lloyd George Czaplewski,Roger Finch,Livermore David,Laura J. V. Piddock,Tony White +27 more
TL;DR: Although a raft of start-up companies are now finding new antibiotic compounds, their development through Phase III depends on financial commitments from large pharmaceutical companies, where the discouraging regulatory environment and the poor likely return on investment remain paramount issues.